With and Without MyD88 and/or CD79B Mutations
1 clinical trials · Condition
◉ Watch With and Without MyD88 and/or CD79B Mutations
| Record | Firm | Date |
|---|---|---|
| Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT05319028) | Calithera Biosciences, Inc | 2022-06-23 |
Track With and Without MyD88 and/or CD79B Mutations automatically
Every clearance here is in the API, with alerts when new ones post.